Genitourinary Cancers

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Real-world data highlighted differences in the timing and severity of belzutifan-related toxicities in VHL-associated tumors and sporadic RCC.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.